General Archive
-
News releasesPromising new antibody treatment for osteoporosis and multiple sclerosis
The new antibody offers hope of an effective new treatment option for millions of people.
-
News releasesHer Majesty Queen Elizabeth II
We at LifeArc are deeply saddened by the passing of Her Majesty Queen Elizabeth II.
-
News releasesLifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
-
News releasesLifeArc helps create new MRC spin-out company
The new company aims to re-programme microbes to enable new materials to be produced – such as drugs and biodegradable…
-
News releasesDriving translational research into childhood rare diseases
Four grants awarded to projects that aim to translate research discoveries into benefits for children affected by rare diseases
-
News releasesNew £4.25 million grant kick starts UK-wide collaborative research effort to end motor neuron disease
Collaboration will work together to find solutions to MND within years, not decades
-
News releasesNew £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
-
News releasesPromising new asthma medicine ready to enter early clinical trials
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe…
-
News releasesPandemic Science Hub to develop better drugs to fight lung disease
New, multi-million pound research programme at the University of Edinburgh will develop treatments for lung infections
-
News releasesAction Medical Research and LifeArc announce a fourth round of funding to support translational research into children’s rare diseases
£1m fund to progress promising translational research addressing a medical need for children and young people
-
News releasesLifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
LONDON, UK, 17 May 2022 — LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has…
-
News releasesLifeArc and Scottish Government work together to drive Scottish research into rare diseases
LifeArc and the Chief Scientist Office (CSO) for the Scottish Government have today jointly awarded a total of £300,000 to…